This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (20)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Topic Collections  • Neurology  • Cerebrovascular Disease  • Cardiovascular System  • Cardiovascular Disease/ Myocardial Infarction  • Alert me on articles by topic  Social Bookmarking   What's this?

Jean-Pierre Boissel, MD

JAMA. 1998;280:1949-1950.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In this issue of THE JOURNAL, He and colleagues¹ present the results of a meta-analysis on the risk of hemorrhagic stroke in patients treated with aspirin at the regimens currently prescribed for the prevention of carotid, coronary, or peripheral artery thrombotic occlusion. This review of a subset of 16 randomized controlled trials of aspirin for the prevention of cerebrovascular accidents, involving more than 55,000 patients, confirms that aspirin, even at the average dosage of 273 mg/d (range, 75-1500 mg/d), increases the risk of cerebral bleeding. Even though the main finding of this study is not new, important lessons can be drawn from this work. First, He et al¹ provide a quantitative estimate of the excess risk due to aspirin instead of the vague notion that the risk is increased. This is another example of a useful application of the meta-analytic approach for evaluation of adverse events, ie, . . . [Full Text of this Article]

From the Clinical Pharmacology Department, Hôpital Neuro-Cardiologique, Lyon, France.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Aspirin and Risk of Hemorrhagic Stroke: A Meta-analysis of Randomized Controlled Trials
Jiang He, Paul K. Whelton, Brian Vu, and Michael J. Klag
JAMA. 1998;280(22):1930-1935.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials
Sanmuganathan et al.
Heart 2001;85:265-271.
ABSTRACT | FULL TEXT  

Antithrombotic Agents in Coronary Artery Disease
Cairns et al.
Chest 2001;119 :228S-252S.
FULL TEXT  

Determination of who may derive most benefit from aspirin in primary prevention: subgroup results from a randomised controlled trial
Meade and Brennan
BMJ 2000;321:13-17.
ABSTRACT | FULL TEXT  

Coronary and cardiovascular risk estimation for primary prevention: validation of a new Sheffield table in the 1995 Scottish health survey population
Wallis et al.
BMJ 2000;320:671-676.
ABSTRACT | FULL TEXT  

Aspirin and Risk of Hemorrhagic Stroke
Colwell et al.
JAMA 1999;282:731-733.
FULL TEXT  

New look at myocardial infarction: toward a better aspirin
Bing et al.
Cardiovasc Res 1999;43:25-31.
ABSTRACT | FULL TEXT